A Phase 2 interventional study of Pneumococcal Conjugate Vaccine (V114) and PNEUMOVAX® 23 in Pneumococcal Infections, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-13.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Pneumococcal Infections by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Pneumococcal Infections · Merck & Co., Inc.
Among the 43 studies in Pneumococcal Infections by Merck & Co., Inc, this one is the 18th largest by enrollment, is the only one that started in 2012, is one of 5 in phase 2, and was the 7th registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →1 of the 43 studies in Pneumococcal Infections by Merck & Co., Inc is open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States
Ages 2 mo–15 mo · Healthy volunteers
By country, each count listing its studies:
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 7 · Phase 3 31 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2012.
This study's enrollment of 692 is above the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 518 across the 43 interventional studies. Of the 42 that completed or were terminated, 40 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 43 studies in Pneumococcal Infections by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to see if an investigational vaccine for Streptococcus pneumonia disease (V114) has comparable safety, tolerability, and antibody response to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX® 23) and 13-valent Pneumococcal Conjugate Vaccine (PREVNAR 13®) when administered to healthy adults 50 years of age or older.
The primary hypothesis is the serotype-specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) as measured by the pneumococcal electrochemiluminescence (Pn ECL) assay at one month postvaccination in subjects who receive V114 will be noninferior to those measured in subjects who receive PNEUMOVAX® 23.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Without fever for 72 hours prior to vaccination
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
Biological: Pneumococcal Conjugate Vaccine (V114)
Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.
Biological: PNEUMOVAX® 23
Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.
Biological: PREVNAR 13®
15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose.
13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
Percentage of Participants With an Adverse Event
An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse experience.
Time frame: All AEs: up to 14 days after vaccination; Serious Adverse Events (SAEs): up to 6 months after vaccination
Percentage of Participants With an Injection-site Adverse Event Reported With >=2% Incidence in One or More Vaccination Groups
Injection-site AEs reported by \>=2% of participants in one or more vaccination groups were assessed.
Time frame: Up to Day 14 postvaccination
Percentage of Participants With a Systemic Adverse Event Reported With >=2% Incidence in One or More Vaccination Groups
Systemic AEs reported by \>=2% of participants in one or more vaccination groups were assessed.
Time frame: Up to Day 14 postvaccination
Percentage of Participants With a Serious Adverse Event
A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.
Time frame: Up to 6 months postvaccination
Percentage of Participants With a Vaccine-related Serious Adverse Event
A SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. SAEs deemed by the investigator to be possibly, probably, or definitely related to study vaccine were reported.
Time frame: Up to 6 months postvaccination
Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) Antibodies
Pneumococcal serotype-specific IgG was measured in serum using an electrochemiluminescence (ECL) assay.
Time frame: One month postvaccination
Geometric Mean Titer (GMT) of Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA) Antibodies
OPA for the serotypes contained in V114 was determined using a Multiplex Opsonophagocytic Assay (MOPA-4)
Time frame: One month postvaccination
This trial was conducted at 25 trial centers: 10 in the United States; 2 in Canada; 2 in Denmark; 2 in Israel; 2 in Norway, 3 in Poland, 2 in Spain and 2 in Sweden.
| Milestone | V114 | PNEUMOVAX® 23 | PREVNAR 13® |
|---|---|---|---|
| Started | 230 | 231 | 231 |
| Vaccinated | 230 | 231 | 230 |
| Completed | 226 | 225 | 226 |
| Not completed | 4 | 6 | 5 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 5 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 | 2 |
| Withdrew: Randomized but not vaccinated | 0 | 0 | 1 |
An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse experience.
| Percentage of Participants | V114 | PNEUMOVAX® 23 | PREVNAR 13® |
|---|---|---|---|
| Percentage of Participants With an Adverse Event | 75.1 | 68.3 | 65.7 |
Injection-site AEs reported by \>=2% of participants in one or more vaccination groups were assessed.
| Percentage of Participants | V114 | PNEUMOVAX® 23 | PREVNAR 13® |
|---|---|---|---|
| Injection site erythema | 14.8 | 14.8 | 13.0 |
| Injection site induration | 14.8 | 10.4 | 12.6 |
| Injection site pain | 60.3 | 51.3 | 53.0 |
| Injection site pruritus | 3.1 | 1.3 | 2.2 |
| Injection site swelling | 20.1 | 10.9 | 18.3 |
| Injection site warmth | 0.9 | 0.0 | 2.2 |
Systemic AEs reported by \>=2% of participants in one or more vaccination groups were assessed.
| Percentage of Participants | V114 | PNEUMOVAX® 23 | PREVNAR 13® |
|---|---|---|---|
| Percentage of Participants With a Systemic Adverse Event Reported With >=2% Incidence in One or More Vaccination Groups | 48.5 | 43.9 | 45.6 |
A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.
| Percentage of Participants | V114 | PNEUMOVAX® 23 | PREVNAR 13® |
|---|---|---|---|
| Percentage of Participants With a Serious Adverse Event | 1.7 | 3.0 | 2.2 |
A SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. SAEs deemed by the investigator to be possibly, probably, or definitely related to study vaccine were reported.
| Percentage of Participants | V114 | PNEUMOVAX® 23 | PREVNAR 13® |
|---|---|---|---|
| Percentage of Participants With a Vaccine-related Serious Adverse Event | 0.0 | 0.0 | 0.0 |
Pneumococcal serotype-specific IgG was measured in serum using an electrochemiluminescence (ECL) assay.
| µg/mL | V114 | PNEUMOVAX® 23 | PREVNAR 13® |
|---|---|---|---|
| Serotype 1 | 3.76 (3.05 to 4.65) | 3.30 (2.68 to 4.07) | 3.12 (2.54 to 3.82) |
| Serotype 3 | 1.13 (0.96 to 1.35) | 0.57 (0.47 to 0.68) | 0.56 (0.47 to 0.66) |
| Serotype 4 | 1.96 (1.59 to 2.41) | 1.03 (0.83 to 1.27) | 2.09 (1.70 to 2.56) |
| Serotype 5 | 3.99 (3.23 to 4.92) | 2.70 (2.21 to 3.30) | 2.76 (2.21 to 3.44) |
| Serotype 6A | 4.88 (3.73 to 6.39) | 1.14 (0.90 to 1.43) | 4.86 (3.86 to 6.13) |
| Serotype 6B | 5.43 (4.11 to 7.17) | 2.01 (1.58 to 2.57) | 2.81 (2.19 to 3.62) |
| Serotype 7F | 4.59 (3.72 to 5.66) | 3.74 (3.00 to 4.65) | 6.06 (4.91 to 7.48) |
| Serotype 9V | 4.05 (3.32 to 4.93) | 2.72 (2.21 to 3.36) | 3.41 (2.77 to 4.20) |
| Serotype 14 | 8.56 (6.86 to 10.69) | 8.13 (6.38 to 10.36) | 8.90 (7.08 to 11.18) |
| Serotype 18C | 8.00 (6.62 to 9.68) | 4.66 (3.73 to 5.82) | 6.83 (5.68 to 8.20) |
| Serotype 19A | 9.36 (7.66 to 11.44) | 6.99 (5.67 to 8.61) | 11.36 (9.28 to 13.92) |
| Serotype 19F | 3.35 (2.67 to 4.21) | 4.17 (3.32 to 5.24) | 4.80 (3.81 to 6.04) |
| Serotype 22F | 5.21 (4.25 to 6.39) | 1.98 (1.61 to 2.44) | 0.38 (0.32 to 0.44) |
| Serotype 23F | 5.55 (4.33 to 7.12) | 1.82 (1.44 to 2.30) | 3.41 (2.62 to 4.43) |
| Serotype 33F | 11.56 (9.27 to 14.40) | 8.26 (6.52 to 10.47) | 0.85 (0.70 to 1.03) |
OPA for the serotypes contained in V114 was determined using a Multiplex Opsonophagocytic Assay (MOPA-4)
| Titer | V114 | PNEUMOVAX® 23 | PREVNAR 13® |
|---|---|---|---|
| Serotype 1 | 208.03 (156.36 to 276.78) | 117.87 (87.11 to 159.49) | 115.75 (85.72 to 156.31) |
| Serotype 3 | 595.16 (498.23 to 710.95) | 313.83 (256.64 to 383.76) | 256.76 (212.08 to 310.85) |
| Serotype 4 | 2875.79 (2215.61 to 3732.69) | 1099.88 (804.01 to 1504.63) | 3001.63 (2380.57 to 3784.72) |
| Serotype 5 | 712.21 (537.78 to 943.22) | 288.41 (210.03 to 396.06) | 372.35 (271.76 to 510.19) |
| Serotype 6A | 4216.34 (2977.07 to 5971.49) | 490.60 (325.94 to 738.44) | 5251.47 (4114.87 to 6702.00) |
| Serotype 6B | 6469.99 (4775.27 to 8766.16) | 1630.20 (1174.34 to 2263.03) | 4207.86 (3212.46 to 5511.70) |
| Serotype 7F | 5148.66 (4170.62 to 6356.06) | 3665.62 (2722.58 to 4935.30) | 7816.74 (6358.89 to 9608.81) |
| Serotype 9V | 3024.34 (2338.72 to 3910.96) | 1674.44 (1252.72 to 2238.12) | 2471.10 (1882.58 to 3243.60) |
| Serotype 14 | 4352.27 (3374.62 to 5613.15) | 3572.27 (2667.12 to 4784.61) | 4478.38 (3647.04 to 5499.22) |
| Serotype 18C | 4631.86 (3730.53 to 5750.96) | 2438.57 (1839.33 to 3233.04) | 3358.41 (2665.75 to 4231.06) |
| Serotype 19A | 3391.18 (2755.18 to 4174.00) | 2682.65 (2095.62 to 3434.12) | 4186.28 (3421.20 to 5122.46) |
| Serotype 19F | 1201.17 (906.20 to 1592.15) | 1581.60 (1211.55 to 2064.67) | 1946.04 (1547.41 to 2447.35) |
| Serotype 22F | 8329.52 (6542.87 to 10604.06) | 4382.78 (3359.60 to 5717.58) | 57.45 (37.29 to 88.50) |
| Serotype 23F | 2217.18 (1588.99 to 3093.71) | 378.41 (262.42 to 545.67) | 1197.80 (836.80 to 1714.53) |
| Serotype 33F | 31116.90 (24612.69 to 39339.94) | 27560.15 (21471.19 to 35375.88) | 3129.94 (2441.58 to 4012.38) |
Collected over Up to 6 months postvaccination. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| V114 | 0/229 (0%) | 4/229 (1.7%) | 167/229 (72.9%) |
| PNEUMOVAX® 23 | 1/230 (0.4%) | 7/230 (3%) | 149/230 (64.8%) |
| PREVNAR 13® | 0/230 (0%) | 5/230 (2.2%) | 141/230 (61.3%) |
| Event | V114 | PNEUMOVAX® 23 | PREVNAR 13® |
|---|---|---|---|
| Coronary artery occlusionCardiac disorders | 1/229 | 0/230 | 0/230 |
| AppendicitisInfections and infestations | 1/229 | 1/230 | 0/230 |
| Anal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/229 | 0/230 | 0/230 |
| AnxietyPsychiatric disorders | 1/229 | 0/230 | 0/230 |
| Cardiac failureCardiac disorders | 0/229 | 1/230 | 0/230 |
| Myocardial infarctionCardiac disorders | 0/229 | 1/230 | 0/230 |
| VertigoEar and labyrinth disorders | 0/229 | 1/230 | 1/230 |
| Gastrointestinal disorderGastrointestinal disorders | 0/229 | 1/230 | 0/230 |
| DeathGeneral disorders | 0/229 | 1/230 | 0/230 |
| CholecystitisHepatobiliary disorders | 0/229 | 0/230 | 1/230 |
| Event | V114 | PNEUMOVAX® 23 | PREVNAR 13® |
|---|---|---|---|
| Injection site painGeneral disorders | 138/229 | 118/230 | 122/230 |
| MyalgiaMusculoskeletal and connective tissue disorders | 69/229 | 60/230 | 50/230 |
| FatigueGeneral disorders | 57/229 | 63/230 | 55/230 |
| Injection site swellingGeneral disorders | 46/229 | 25/230 | 42/230 |
| HeadacheNervous system disorders | 40/229 | 41/230 | 42/230 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 41/229 | 26/230 | 29/230 |
| Injection site erythemaGeneral disorders | 34/229 | 34/230 | 30/230 |
| Injection site indurationGeneral disorders | 34/229 | 24/230 | 29/230 |
The baseline analysis population consisted of all randomized participants who received study vaccine.
| Age, Customized(Participants) | V114 | PNEUMOVAX® 23 | PREVNAR 13® | Total |
|---|---|---|---|---|
| 50 to 64 years | 79 | 80 | 80 | 239 |
| 65 to 74 years | 75 | 76 | 74 | 225 |
| >= 75 years | 76 | 75 | 76 | 227 |
| Sex: Female, Male(Participants) | V114 | PNEUMOVAX® 23 | PREVNAR 13® | Total |
|---|---|---|---|---|
| Female | 122 | 123 | 122 | 367 |
| Male | 108 | 108 | 108 | 324 |
| Ethnicity (NIH/OMB)(Participants) | V114 | PNEUMOVAX® 23 | PREVNAR 13® | Total |
|---|---|---|---|---|
| Hispanic or Latino | 14 | 20 | 14 | 48 |
| Not Hispanic or Latino | 216 | 211 | 215 | 642 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | V114 | PNEUMOVAX® 23 | PREVNAR 13® | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 5 | 6 | 3 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 2 | 2 |
| Black or African American | 10 | 6 | 12 | 28 |
| White | 212 | 217 | 212 | 641 |
| More than one race | 3 | 2 | 0 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Mar 2012 to primary completion in Feb 2013, 11 months.
Results were first posted in Dec 2018, 5 years 9 months after primary completion.
Of 23 phase 2 interventional studies under Pneumococcal Infections, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal Conjugate Vaccine